Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 3Withdrawn 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER_GOV 1OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 78Vincristine 69obinutuzumab 67Doxorubicin 66Prednisone 65Biopsy 64Magnetic Resonance Spectroscopy 62zanubrutinib 52Lenalidomide 52Dexamethasone 49Methotrexate 43Cytarabine 43blinatumomab 40acalabrutinib 37Immunotherapy, Adoptive 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × EPOCH protocol × Lymphoid × Clear all
NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
132 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06520163 2025-12-04

Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
99 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡